Squamous Cell Carcinoma Of The Head And Neck – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of SCCHN comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of SCCHN for each country, as well as annualized case counts projected to the national population.
In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.
Clarivate Epidemiology’s SCCHN forecast will answer the following questions:
In developing countries, what impact will economic growth and development have on the number of people diagnosed with SCCHN each year?
Of all people diagnosed with SCCHN, how many in each of the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of SCCHN over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
Squamous Cell Carcinoma Of The Head And Neck - Epidemiology - Epidemiology Dashboard
Squamous Cell Carcinoma of the Head and Neck Epidemiology Dashboard
Aishwarya S. Ambat
Aishwarya S. Ambat, M.P.H., Epidemiologist , Epidemiology. She received her M.P.H. from the Manipal Academy of Higher Education in India and holds a bachelor’s degree in physiotherapy. Her areas of interest are rheumatic disease and cancer epidemiology.